Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis
Adam Ioannou(The Royal Free Hospital), Marianna Fontana(Amyloidosis Foundation), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), Richard P. Steeds(University Hospitals Birmingham NHS Foundation Trust), Scott D. Solomon(Brigham and Women's Hospital), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Carol Whelan(The Royal Free Hospital), Ashutosh Wechalekar(University College Hospital), Yousuf Razvi(The Royal Free Hospital), Aldostefano Porcari(Azienda Sanitaria Universitaria Integrata di Trieste), Muhammad U. Rauf(The Royal Free Hospital), William E. Moody(University Hospitals Birmingham NHS Foundation Trust), Carlo Fumagalli(Azienda Ospedaliero-Universitaria Careggi), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Aviva Petrie(Eastman Dental Hospital)
Cited by 49
Related Papers
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k